Literature DB >> 25182645

Nitrotriazole- and imidazole-based amides and sulfonamides as antitubercular agents.

Maria V Papadopoulou1, William D Bloomer2, Howard S Rosenzweig3, Alexander Arena4, Francisco Arrieta4, Joseph C J Rebolledo4, Diane K Smith4.   

Abstract

Twenty-three 3-nitrotriazole-based and 2-nitroimidazole-based amides and sulfonamides were screened for antitubercular (anti-TB) activity in aerobic Mycobacterium tuberculosis H37Rv by using the BacTiter-Glo (BTG) microbial cell viability assay. In general, 3-nitrotriazole-based sulfonamides demonstrated anti-TB activity, whereas 3-nitrotriazole-based amides and 2-nitroimidazole-based amides and sulfonamides were inactive. Three 3-nitrotriazole-based sulfonamides (compounds 4, 2, and 7) demonstrated 50% inhibitory concentration (IC50), IC90, and MIC values of 0.38, 0.43, and 1.56 μM (compound 4), 0.57, 0.98, and 3.13 μM (compound 2), and 0.79, 0.87, and 3.13 μM (compound 7), respectively. For 3-nitrotriazole-based sulfonamides, anti-TB activity increased with lipophilicity, whereas the one-electron reduction potential (E1/2) did not play a role. 2-Nitroimidazole-based analogs, which were inactive in the BTG assay, were significantly more active in the low-oxygen assay and more active than the 3-nitrotriazoles. All active nitrotriazoles in the BTG assay were similarly active or more potent (lower MIC values) against resistant strains, with the exception of compounds 2, 3, 4, and 8, which demonstrated greater MIC values against isoniazid-resistant strains. Five 3-nitrotriazole-based sulfonamides demonstrated activity in infected murine J774 macrophages, causing log reductions similar to those seen with rifampin. However, some compounds caused toxicity in uninfected macrophages. In conclusion, the classes of 3-nitrotriazole-based amides and sulfonamides merit further investigation as potential antitubercular agents.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25182645      PMCID: PMC4249394          DOI: 10.1128/AAC.03644-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence.

Authors:  L G Wayne; L G Hayes
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

2.  Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.

Authors:  Sang Hyun Cho; Saradee Warit; Baojie Wan; Chang Hwa Hwang; Guido F Pauli; Scott G Franzblau
Journal:  Antimicrob Agents Chemother       Date:  2007-01-08       Impact factor: 5.191

3.  Structures of coenzyme F(420) in Mycobacterium species.

Authors:  T B Bair; D W Isabelle; L Daniels
Journal:  Arch Microbiol       Date:  2001-07       Impact factor: 2.552

Review 4.  Tuberculosis - metabolism and respiration in the absence of growth.

Authors:  Helena I M Boshoff; Clifton E Barry
Journal:  Nat Rev Microbiol       Date:  2005-01       Impact factor: 60.633

5.  Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis.

Authors:  Ujjini H Manjunatha; Helena Boshoff; Cynthia S Dowd; Liang Zhang; Thomas J Albert; Jason E Norton; Lacy Daniels; Thomas Dick; Siew Siew Pang; Clifton E Barry
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-30       Impact factor: 11.205

6.  Reductive metabolism of the nitroimidazole-based hypoxia-selective cytotoxin NLCQ-1 (NSC 709257).

Authors:  Maria V Papadopoulou; Ming Ji; Mira K Rao; William D Bloomer
Journal:  Oncol Res       Date:  2003       Impact factor: 5.574

Review 7.  NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug.

Authors:  Maria V Papadopoulou; William D Bloomer
Journal:  Clin Cancer Res       Date:  2003-11-15       Impact factor: 12.531

8.  Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis.

Authors:  L G Wayne; H A Sramek
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

9.  Novel 3-nitro-1H-1,2,4-triazole-based compounds as potential anti-Chagasic drugs: in vivo studies.

Authors:  Maria V Papadopoulou; William D Bloomer; Howard S Rosenzweig; Rachel Ashworth; Shane R Wilkinson; Marcel Kaiser; Grasiella Andriani; Ana Rodriguez
Journal:  Future Med Chem       Date:  2013-10       Impact factor: 3.808

Review 10.  Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis.

Authors:  Clifton E Barry; Helena I M Boshoff; Cynthia S Dowd
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

View more
  7 in total

Review 1.  The Diverse Biological Activity of Recently Synthesized Nitro Compounds.

Authors:  Saúl Noriega; Jaime Cardoso-Ortiz; Argelia López-Luna; Ma Del Refugio Cuevas-Flores; Juan Armando Flores De La Torre
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-05

2.  Design and synthesis of novel quinoxaline derivatives as potential candidates for treatment of multidrug-resistant and latent tuberculosis.

Authors:  Mery Santivañez-Veliz; Silvia Pérez-Silanes; Enrique Torres; Elsa Moreno-Viguri
Journal:  Bioorg Med Chem Lett       Date:  2016-03-18       Impact factor: 2.823

3.  Purification and synergistic antibacterial activity of arginine derived cyclic dipeptides, from Achromobacter sp. associated with a rhabditid entomopathogenic nematode against major clinically relevant biofilm forming wound bacteria.

Authors:  Indira Deepa; Sasidharan N Kumar; Ravikumar S Sreerag; Vishnu S Nath; Chellapan Mohandas
Journal:  Front Microbiol       Date:  2015-08-25       Impact factor: 5.640

Review 4.  Advances in Drug Discovery of New Antitubercular Multidrug-Resistant Compounds.

Authors:  Guilherme Felipe Dos Santos Fernandes; Chung Man Chin; Jean Leandro Dos Santos
Journal:  Pharmaceuticals (Basel)       Date:  2017-06-01

5.  Novel Imidazole Aldoximes with Broad-Spectrum Antimicrobial Potency against Multidrug Resistant Gram-Negative Bacteria.

Authors:  Mirjana Skočibušić; Renata Odžak; Alma Ramić; Tomislav Smolić; Tomica Hrenar; Ines Primožič
Journal:  Molecules       Date:  2018-05-18       Impact factor: 4.411

6.  Easy-To-Access Quinolone Derivatives Exhibiting Antibacterial and Anti-Parasitic Activities.

Authors:  Richard M Beteck; Audrey Jordaan; Ronnett Seldon; Dustin Laming; Heinrich C Hoppe; Digby F Warner; Setshaba D Khanye
Journal:  Molecules       Date:  2021-02-20       Impact factor: 4.411

Review 7.  An insight on medicinal attributes of 1,2,4-triazoles.

Authors:  Ranjana Aggarwal; Garima Sumran
Journal:  Eur J Med Chem       Date:  2020-07-27       Impact factor: 6.514

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.